1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,705 | 0,830 | 12:18 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Arecor Therapeutics - Posting of Annual Report and Notice of AGMm | - | RNS | ||
| 13.04. | Arecor Therapeutics swings to annual profit; hails insulin product | 1 | Alliance News | ||
| 13.04. | Arecor Therapeutics - Final Results | - | RNS | ||
| 30.03. | Arecor Therapeutics - Notice of FY25 Results | - | RNS | ||
| 26.03. | Arecor erhält Meilensteinzahlung von 0,5 Mio. US-Dollar aus Vereinbarung mit Ligand | 1 | Investing.com Deutsch | ||
| 26.03. | Arecor receives $0.5m milestone from Ligand deal | 1 | Investing.com | ||
| 26.03. | Arecor Therapeutics - Ligand Pharmaceuticals Milestone Payment | - | RNS | ||
| 09.03. | Arecor Therapeutics - Arecor to present at Oppenheimer conference | - | RNS | ||
| ARECOR THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 09.02. | Arecor Therapeutics revenue falls after Tetris Pharma operations cease | 1 | Alliance News | ||
| 09.02. | Arecor's ultra-concentrated insulin advances with Sequel partnership | 2 | Investing.com | ||
| 09.02. | Arecor treibt ultrakonzentriertes Insulin durch Partnerschaft mit Sequel voran | 1 | Investing.com Deutsch | ||
| 09.02. | Arecor Therapeutics - 2025 Business Update | - | RNS | ||
| 06.01. | Arecor Therapeutics - Fireside Panel Discussion on Diabetes sector | - | RNS | ||
| 09.12.25 | Arecor, Sequel Med Tech to host virtual panel on diabetes care | 2 | Investing.com | ||
| 09.12.25 | Arecor Therapeutics - Arecor and Sequel Med Tech to host fireside panel | - | RNS | ||
| 04.11.25 | Arecor Therapeutics - Enhanced IP Coverage: AT278 & Oral Peptide Program | - | RNS | ||
| 25.09.25 | Arecor Therapeutics PLC: Arecor announces Co-development Agreement with US Insulin Pump Device Company for AT278 & Sale of Royalty Rights and Technology Access Fees for AT220 and AT292 | 181 | GlobeNewswire (Europe) | This announcement contains inside information for the purposes of the retained UK version of the EU Market Abuse Regulation (EU) 596/2014 ("UK MAR"). Arecor Therapeutics plc("Arecor" or the "Company")... ► Artikel lesen | |
| 19.05.25 | Skye Bioscience, Inc.: Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab | 519 | GlobeNewswire (Europe) | SAN DIEGO, May 19, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) ("Skye"), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TANGO THERAPEUTICS | 22,060 | 0,00 % | Stifel raises Tango Therapeutics stock price target on drug combo potential | ||
| ERASCA | 9,080 | 0,00 % | Erasca, Inc.: Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors | Robust monotherapy efficacy in KRAS G12X NSCLC: 62% uORR in 2L+ and 75% uORR in post-ICI/platinum 2/3L at 16-32 mg QD PAD, and 64% uORR in 2L+ at 24-32 mg QD RDE Robust monotherapy efficacy in 2L... ► Artikel lesen | |
| QIAGEN | 28,720 | +0,74 % | QIAGEN bremst Erwartungen: QuantiFERON schwächelt, Hoffnung auf zweites Halbjahr | QIAGEN startet schwach ins Jahr: Umsatz stagniert, QuantiFERON belastet - Prognose gesenkt, Hoffnung liegt auf stärkerem zweiten Halbjahr. Der Diagnostik- und Life-Sciences-Konzern QIAGEN ist verhalten... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 41,350 | 0,00 % | Here is Why Structure Therapeutics (GPCR) is One of the Top Biotech Names to Look at | ||
| BEAM THERAPEUTICS | 29,390 | 0,00 % | Beam Therapeutics (BEAM) Reveals Encouraging Results From Risto-Cel Phase 1/2 BEACON Study | ||
| ADMA BIOLOGICS | 10,600 | 0,00 % | Summers Value Fund adds TBPH, exits ADMA among Q1 moves | ||
| APOGEE THERAPEUTICS | 82,03 | 0,00 % | Apogee Therapeutics Inc. (APGE): Primary Challenger to Established Blockbusters | ||
| COGENT BIOSCIENCES | 35,880 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST) | Bezuclastinib NDA submitted under the FDA's RTOR program based on positive results from Phase 3 PEAK trial; bezuclastinib previously granted Breakthrough Therapy Designation in GISTBezuclastinib combination... ► Artikel lesen | |
| IMMUNOVANT | 26,950 | 0,00 % | Immunovant Inc.: Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED) | Phase 3 studies of batoclimab in thyroid eye disease (TED) each failed to meet their primary endpoint; safety results were consistent with previous findingsPatients in the TED studies demonstrated... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 20,810 | 0,00 % | Summit Therapeutics leads all large-cap healthcare stocks in YoY CapEx growth | ||
| KINIKSA PHARMACEUTICALS | 53,00 | 0,00 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution | - ARCALYST- (rilonacept) Q1 2026 net product revenue of $214.3 million, representing 56% year-over-year growth -- ARCALYST 2026 expected net product revenue increased to $930 - $945 million -- KPL-387... ► Artikel lesen | |
| DESIGN THERAPEUTICS | 15,780 | +23,18 % | Design Therapeutics, Inc.: Design Therapeutics Announces First Quarter 2026 Financial Results and Recent Business Updates | Additional Detail Provided for RESTORE-FA (DT-216P2) Trial Design, Dosing and Endpoints David Shapiro, M.D., Appointed to Board of Directors, Strengthening Clinical and Regulatory Expertise Cash and... ► Artikel lesen | |
| DYNE THERAPEUTICS | 17,415 | 0,00 % | Dyne Therapeutics vor Quartalszahlen: Markteinführung von DMD-Therapie im Fokus | ||
| INHIBRX BIOSCIENCES | 125,06 | 0,00 % | Morning Market Movers: Axe Compute, Inhibrx Biosciences, Huachen AI Parking Management Technology, 1-800-FLOWERS.COM See Big Swings | OTTAWA (dpa-AFX) - At 9:00 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,310 | 0,00 % | Recursion Expands Strategic Partnership with Citeline to Advance Its AI-Enabled ClinTech Platform | NEW YORK and SALT LAKE CITY, March 31, 2026 (GLOBE NEWSWIRE) -- Citeline, a leader in clinical solutions for the life sciences industry, today announced an expanded strategic partnership with Recursion... ► Artikel lesen |
Das Unternehmen ARECOR THERAPEUTICS PLC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,930 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ARECOR THERAPEUTICS PLC finden Sie auf Wallstreet Online.